Endeavor Health

Running trials

• Not yet recruiting

  A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity

  NCT07919405· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.

  NCT06458907· P+F Products + Features USA Inc.· Source

• Recruiting

  A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

  NCT07668414· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

  NCT07817251· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  WATER IV PCa (AS Sub-study)

  NCT07650448· PROCEPT BioRobotics· Source

• Recruiting

  AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

  NCT07720271· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

  NCT07733765· Phase 3· Pfizer· Source

• Recruiting

  Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

  NCT07684144· Phase 3· Amgen· Source

• Recruiting

  Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  NCT07684235· Phase 3· Amgen· Source

• Recruiting

  An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

  NCT07665437· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study

  NCT07324031· AtaCor Medical, Inc.· Source

• Enrolling by invitation

  Fasenra: An Asthma Study

  NCT07654842· Phase 4· Endeavor Health· Source

• Recruiting

  Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)

  NCT07637734· Phase 3· Verrica Pharmaceuticals Inc.· Source

• Recruiting

  A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

  NCT07595549· Phase 3· Pfizer· Source

• Recruiting

  A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy

  NCT07675135· Phase 3· Harmony Biosciences Management, Inc.· Source

• Enrolling by invitation

  The Implementation of Genetic Risk for Colorectal Cancer Screening

  NCT07621757· Endeavor Health· Source

• Recruiting

  A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

  NCT07599813· Phase 2· Apollo Therapeutics Ltd· Source

• Recruiting

  A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

  NCT07564414· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  NCT07575399· Phase 3· Amgen· Source

• Active, not recruiting

  AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

  NCT07503210· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Patient Quality of Recovery After TAVR With Different Sedation Regimens

  NCT07556523· Phase 4· David Lyubashevsky· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  NCT07351045· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  The NAVIGATE-PCI Registry: A New Approach to VIew CT-derived Guidance Ahead of Stenting To Plan Efficient PCI

  NCT07479433· HeartFlow, Inc.· Source

• Recruiting

  A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

  NCT07431177· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

• Recruiting

  AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

  NCT07339423· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Eli Lilly and Company· Source

• Recruiting

  NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study

  NCT06604884· Medtronic Neurovascular Clinical Affairs· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

• Enrolling by invitation

  Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

  NCT07256392· Phase 3· Celldex Therapeutics· Source

• Recruiting

  REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

  NCT07213778· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

  NCT07228390· Phase 2· Pfizer· Source

• Recruiting

  Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

  NCT07190209· Phase 3· Sanofi· Source

• Recruiting

  A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

  NCT07029828· Phase 3· Pfizer· Source

• Recruiting

  AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

  NCT06959524· Boston Scientific Corporation· Source

• Recruiting

  A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

  NCT07005154· Phase 2· Astellas Pharma Global Development, Inc.· Source

• Active, not recruiting

  A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

  NCT07076199· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

  NCT07029711· Phase 3· Pfizer· Source

• Recruiting

  A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

  NCT06997497· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)

  NCT06464926· Enterra Medical, Inc.· Source

• Active, not recruiting

  A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

  NCT07011667· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

  NCT06931405· Phase 2· Blueprint Medicines Corporation· Source

• Recruiting

  Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

  NCT06865651· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  TECTONIC CAD IVL IDE Study

  NCT06885177· Abbott Medical Devices· Source

• Recruiting

  A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

  NCT06873945· Phase 3· Pfizer· Source

• Active, not recruiting

  A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

  NCT06840392· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  WATER IV Prostate Cancer

  NCT06651632· PROCEPT BioRobotics· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

  NCT06548360· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Phase 3· Pfizer· Source

Showing 50 of 98.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity9 recruiting
• Prostate cancer5 recruiting
• Alopecia areata4 recruiting
• Stroke4 recruiting
• Type 2 diabetes4 recruiting
• Colorectal cancer3 recruiting
• Aortic stenosis2 recruiting
• Atrial fibrillation2 recruiting
• Brain aneurysm2 recruiting
• Chronic spontaneous urticaria2 recruiting
• Coronary artery disease2 recruiting
• Deep vein thrombosis and pulmonary embolism2 recruiting
• Lung cancer2 recruiting
• Ovarian cancer2 recruiting
• Vitiligo2 recruiting
• Aortic aneurysm1 recruiting
• Asthma1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Bladder cancer1 recruiting
• COPD1 recruiting
• Crohn's disease1 recruiting
• Epilepsy1 recruiting
• Heart failure1 recruiting
• Hidradenitis suppurativa1 recruiting
• High blood pressure1 recruiting
• Metastatic breast cancer1 recruiting
• Migraine1 recruiting
• Mild cognitive impairment1 recruiting
• Multiple sclerosis1 recruiting
• Narcolepsy1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Pancreatic cancer1 recruiting
• Parkinson disease1 recruiting
• Restless legs syndrome1 recruiting
• Triple-negative breast cancer1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Completed

  Innovative Automated Insulin Delivery System for Type 2 Diabetes

  NCT06853990· Deka Research and Development· Source

• Recruiting

  A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

  NCT06717698· Phase 2· Novo Nordisk A/S· Source

• Completed

  A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

  NCT06238817· Phase 3· Incyte Corporation· Source

• Completed

  A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

  NCT06269107· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06221969· Phase 3· Novo Nordisk A/S· Source

• Completed

  Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec

  NCT06238778· Phase 2· Diasome Pharmaceuticals· Source

• Completed

  SYMPHONY-PE Study for Treatment of Pulmonary Embolism

  NCT06062329· Imperative Care, Inc.· Source

• Completed

  A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

  NCT06131437· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06065540· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

  NCT05795153· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Amgen· Source

• Completed

  A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

  NCT05174221· Phase 1· Takeda· Source

• Completed

  Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis

  NCT05272150· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec

  NCT05352815· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

  NCT05259033· Phase 3· Novo Nordisk A/S· Source

• Completed

  Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue

  NCT04972097· Angiodynamics, Inc.· Source

• Completed

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

  NCT05013229· Phase 3· Novo Nordisk A/S· Source

• Completed

  Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)

  NCT05172024· NYU Langone Health· Source

• Completed

  A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

  NCT05035082· Phase 4· Novo Nordisk A/S· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Eli Lilly and Company· Source

• Completed

  Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

  NCT04179175· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Mechanistic Characterization of Uterine Pain

  NCT04145518· Phase 4· Endeavor Health· Source

• Completed

  A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

  NCT03819153· Phase 3· Novo Nordisk A/S· Source

• Completed

  Rostock International Parkinson's Disease Study (ROPAD)

  NCT03866603· CENTOGENE GmbH Rostock· Source

• Completed

  Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)

  NCT03849716· Sanofi· Source

• Completed

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Phase 3· Eli Lilly and Company· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Eli Lilly and Company· Source

• Completed

  Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

  NCT03377491· Phase 3· NovoCure Ltd.· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Pfizer· Source

• Recruiting

  PARTNER 3 Trial - Aortic Valve-in-Valve

  NCT03003299· Edwards Lifesciences· Source

• Completed

  A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

  NCT02815891· Target PharmaSolutions, Inc.· Source

• Completed

  Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02122185· Phase 2· University of Chicago· Source

• Completed

  Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

  NCT02213913· Phase 1/2· University of Chicago· Source

• Completed

  A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

  NCT02163694· Phase 3· AbbVie· Source

• Completed

  A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT01848561· AbbVie· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Chronic spontaneous urticaria15 works · 7 trials